Wang T J, Stafford R S
Institute for Health Policy, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston 02114, USA.
Arch Intern Med. 1998 Sep 28;158(17):1901-6. doi: 10.1001/archinte.158.17.1901.
Prior studies suggest underuse of beta-blockers in patients with coronary artery disease, but these studies have been based on selected populations of recently hospitalized patients.
To describe national patterns and determinants of beta-blocker use in the ambulatory setting.
We analyzed 11745 visits by patients with coronary artery disease to randomly selected, office-based physicians in the National Ambulatory Medical Care Surveys for 1980, 1981, 1985, and 1989 through 1996. We used multiple logistic regression to determine the independent effect of sociodemographic and clinical factors on beta-blocker use.
Beta-blocker use at patient visits.
Beta-blocker use was reported in only 20.9% of office visits by patients with coronary artery disease and no strong contraindications between 1993 and 1996. In multivariate analyses, age younger than 75 years, residence in the Northeast, and visits to cardiologists and internists compared with family and general practitioners predicted greater use of beta-blocker therapy. White race and private insurance also were significant predictors of beta-blocker use between 1980 and 1996. Longitudinal analyses revealed a significant decline in beta-blocker use from 1980 to 1990, followed by a gradual increase in recent years.
Beta-blockers appear to be underused in ambulatory patients with coronary artery disease. Our data suggest that nonclinical factors may influence rates of use, indicating the need for closer scrutiny of variations in physician prescribing practices.
先前的研究表明,冠心病患者对β受体阻滞剂的使用不足,但这些研究是基于近期住院患者的特定人群。
描述门诊环境中β受体阻滞剂使用的全国模式及决定因素。
我们分析了1980年、1981年、1985年以及1989年至1996年期间参加全国门诊医疗调查的冠心病患者对随机选择的门诊医生进行的11745次就诊情况。我们使用多元逻辑回归来确定社会人口统计学和临床因素对β受体阻滞剂使用的独立影响。
患者就诊时β受体阻滞剂的使用情况。
1993年至1996年期间,在无强烈禁忌症的冠心病患者中,只有20.9%的门诊就诊报告使用了β受体阻滞剂。在多变量分析中,年龄小于75岁、居住在东北部、与家庭医生和全科医生相比就诊于心脏病专家和内科医生,这些因素预示着β受体阻滞剂治疗的使用更多。在1980年至1996年期间,白人种族和私人保险也是β受体阻滞剂使用的重要预测因素。纵向分析显示,1980年至1990年β受体阻滞剂的使用显著下降,随后近年来逐渐增加。
门诊冠心病患者中β受体阻滞剂的使用似乎不足。我们的数据表明非临床因素可能影响使用率,这表明需要更密切地审查医生处方行为的差异。